{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary-progressive+Multiple+Sclerosis",
    "query": {
      "condition": "Secondary-progressive Multiple Sclerosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary-progressive+Multiple+Sclerosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T08:27:10.787Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05090371",
      "title": "A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "Disease modifying treatment (DMT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 136,
      "start_date": "2022-03-02",
      "completion_date": "2027-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05090371"
    },
    {
      "nct_id": "NCT06292923",
      "title": "A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Foralumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tiziana Life Sciences LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 54,
      "start_date": "2023-11-15",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 7,
      "location_summary": "North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06292923"
    },
    {
      "nct_id": "NCT04550455",
      "title": "A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Cladribine Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Keith Edwards, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-09-16",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Latham, New York",
      "locations": [
        {
          "city": "Latham",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04550455"
    },
    {
      "nct_id": "NCT06384976",
      "title": "KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive",
        "Multiple Sclerosis",
        "MS"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        },
        {
          "name": "Anti-CD20 mAB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-09-20",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06384976"
    },
    {
      "nct_id": "NCT01188811",
      "title": "Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Chronic Progressive"
      ],
      "interventions": [
        {
          "name": "lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 54,
      "start_date": "2010-10",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188811"
    },
    {
      "nct_id": "NCT07355387",
      "title": "Home Based Functional Balance Intervention for Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Primary Progressive",
        "Multiple Sclerosis (MS) Secondary Progressive",
        "Multiple Sclerosis Acute and Progressive"
      ],
      "interventions": [
        {
          "name": "Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance.",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stretching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 75,
      "start_date": "2025-11-24",
      "completion_date": "2027-11-24",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07355387"
    },
    {
      "nct_id": "NCT01647321",
      "title": "Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Active cycling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Passive cycling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-07",
      "completion_date": "2019-10",
      "has_results": false,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647321"
    },
    {
      "nct_id": "NCT02506751",
      "title": "Open-label Study of Liothyronine in MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Secondary Progressive",
        "Multiple Sclerosis, Primary Progressive"
      ],
      "interventions": [
        {
          "name": "liothyronine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-07",
      "completion_date": "2017-09-18",
      "has_results": false,
      "last_update_posted_date": "2018-02-12",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02506751"
    },
    {
      "nct_id": "NCT04909502",
      "title": "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "EHP-101 25 mg OD",
          "type": "DRUG"
        },
        {
          "name": "EHP-101 25 mg BID",
          "type": "DRUG"
        },
        {
          "name": "EHP-101 50 mg OD",
          "type": "DRUG"
        },
        {
          "name": "EHP-101 50 mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emerald Health Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-10-19",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2022-10-21",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 3,
      "location_summary": "Cullman, Alabama • Fullerton, California • Port Orange, Florida",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909502"
    },
    {
      "nct_id": "NCT02430532",
      "title": "BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 58,
      "start_date": "2015-05",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-06-26T08:27:10.787Z",
      "location_count": 7,
      "location_summary": "Long Beach, California • San Francisco, California • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02430532"
    }
  ]
}